2,3-Butanediol-d8
Based on 1 Customer Validation
2,3-Butanediol-d8 is the deuterium labeled 2,3-Butanediol (HY-128387). 2,3-Butanediol is microbially derived compound that is a discriminating urinary biomarker of Fmo5-/- mice. 2,3-Butanediol prevents age-related increases in the plasma concentration of cholesterol. 2,3-Butanediol has potential applications in the manufacture of printing inks, perfumes, fumigants, moistening and softening agents, plasticizers, and as a carrier for pharmaceuticals.
For research use only. We do not sell to patients.
- Purity : 99.3%
- CAS No.: 347841-77-4
- Formula: C4H2D8O2
- Molecular Weight:98.17
-
Storage:Pure form -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
All Endogenous Metabolite Isoforms
More
Biological Activity
Description
In Vitro
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Application
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 347841-77-4
-
Unlabeled CAS 513-85-9
-
Appearance Liquid
-
Molecular Weight 98.17
-
Formula C4H2D8O2
-
Color Colorless to light yellow
-
SMILES
[2H]C([2H])([2H])C(O)([2H])C(O)([2H])C([2H])([2H])[2H]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
[2]. Zhang L, et al. Mechanism of 2,3-butanediol stereoisomers formation in a newly isolated Serratia sp. T241. Sci Rep. 2016 Jan 12;6:19257. [Content Brief]
[3]. Veeravalli S, et al. Treatment of wild-type mice with 2,3-butanediol, a urinary biomarker of Fmo5-/- mice, decreases plasma cholesterol and epididymal fat deposition. Front Physiol. 2022 Aug 8;13:859681. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)